PMID- 21792700
OWN - NLM
STAT- MEDLINE
DCOM- 20120731
LR  - 20211203
IS  - 1532-2807 (Electronic)
IS  - 1219-4956 (Linking)
VI  - 18
IP  - 2
DP  - 2012 Apr
TI  - pS6 Expression in normal renal parenchyma, primary renal cell carcinomas and 
      their metastases.
PG  - 277-83
LID - 10.1007/s12253-011-9439-y [doi]
AB  - In cancer therapy novel concepts focus on phosphoinositide-3-kinase/protein 
      kinase B/mammalian target of rapamycin (mTOR) inhibitors. In this context, 
      phosphorylated S6 protein of the 40S ribosomal subunit (pS6) overexpression was 
      previously shown to be associated with sensitivity to inhibitors of mTOR. The 
      present study therefore evaluated pS6 expression in normal renal parenchyma 
      (NRP), primary renal cell carcinomas (PRCC) and their metastases. pS6 and pmTOR 
      expression was immunohistochemically analyzed in a tissue microarray (TMA) from 
      localized primary renal cell carcinoma (lPRCC) (n = 35), metastasized primary 
      renal cell carcinoma (mPRCC) (n = 45), their metastases (n = 45), and NRP 
      (n = 45). pS6 expression was stronger in mPRCCs and metastases than in NRP and 
      lPRCCs (p < 0.05). In mPRCCs high-grade and high-stage tumors showed higher pS6 
      levels. pS6 overexpression was more frequently found in metastases (40/45; 88.9%) 
      than in mPRCC (24/45; 53.3%) (p < 0.05). Overexpression of pS6 in metastases 
      without concomitant overexpression in their primary tumors was found in 16/45 
      (35.56%) cases. Patients with pS6 overexpression in mPRCCs but also in metastases 
      showed a tendency to shorter overall survival. pS6 score and pmTOR score 
      correlated positively in NRP and in tumorous tissue (mPRCC and metastases). In 
      conclusion, the present study showed stronger pS6 expression and more frequent 
      overexpression in metastases than in corresponding PRCCs. In approximately 
      one-third of the cases pS6 overexpression was found exclusively in metastases, 
      which is interesting with regard to the association between high pS6 expression 
      and sensitivity to mTOR inhibitor therapy.
FAU - Hager, Martina
AU  - Hager M
AD  - Department of Pathology, Paracelsus Medical University (PMU), Muellner 
      Hauptstrasse 48, 5020, Salzburg, Austria. hager.martina@gmx.at
FAU - Haufe, Heike
AU  - Haufe H
FAU - Alinger, Beate
AU  - Alinger B
FAU - Kolbitsch, Christian
AU  - Kolbitsch C
LA  - eng
PT  - Comparative Study
PT  - Journal Article
DEP - 20110727
PL  - Switzerland
TA  - Pathol Oncol Res
JT  - Pathology oncology research : POR
JID - 9706087
RN  - 0 (Ribosomal Protein S6)
RN  - EC 2.7.1.1 (MTOR protein, human)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
SB  - IM
MH  - Carcinoma, Papillary/metabolism/secondary
MH  - Carcinoma, Renal Cell/*metabolism/*secondary
MH  - Case-Control Studies
MH  - Female
MH  - Humans
MH  - Immunoenzyme Techniques
MH  - Kidney/*metabolism/pathology
MH  - Kidney Neoplasms/*metabolism/*pathology
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - Prognosis
MH  - Ribosomal Protein S6/*metabolism
MH  - Survival Rate
MH  - TOR Serine-Threonine Kinases/metabolism
MH  - Tissue Array Analysis
EDAT- 2011/07/28 06:00
MHDA- 2012/08/01 06:00
CRDT- 2011/07/28 06:00
PHST- 2010/12/29 00:00 [received]
PHST- 2011/07/11 00:00 [accepted]
PHST- 2011/07/28 06:00 [entrez]
PHST- 2011/07/28 06:00 [pubmed]
PHST- 2012/08/01 06:00 [medline]
AID - 10.1007/s12253-011-9439-y [doi]
PST - ppublish
SO  - Pathol Oncol Res. 2012 Apr;18(2):277-83. doi: 10.1007/s12253-011-9439-y. Epub 
      2011 Jul 27.